Document Detail


House dust mite sublingual immunotherapy: a double-blind, placebo-controlled study in elderly patients with allergic rhinitis.
MedLine Citation:
PMID:  23331565     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Immunotherapy in elderly patients is controversial, and there is still no evidence supporting this treatment's safety and efficacy in this population. This study was performed to evaluate the safety and efficacy of specific sublingual immunotherapy for house dust mite (HDM) allergens in patients over 60 years of age with allergic rhinitis and a confirmed allergy to HDM.
OBJECTIVE: This study sought to assess nasal symptoms during HDM season, reduce medication use and monitor for adverse reactions during immunotherapy.
METHODS: One hundred and eleven 60- to 75-year-old patients with allergic rhinitis and a confirmed Dermatophagoides pteronyssinus and Dermatophagoides farinae allergy were included in the study. The patients were individually randomized to active or placebo groups using a double-blind method (NCTO01605760 ClinicalTrials.gov). A total of 51 subjects in the sublingual allergen-specific immunotherapy (SLIT) group (Staloral 300R, Stallergenes, France) and 57 subjects in the placebo group were monitored for 3 years.
RESULTS: Forty-seven patients completed 3 years of SLIT, and 48 subjects finished the placebo treatment in the same time period. The total nasal symptom score decreased by 44% in the active group and 6% in the placebo group after 3 years of SLIT. This difference was only significant in the active group (P < 0.05). At the end of therapy, the total medication score of the active group decreased significantly by a maximum of 51% (P < 0.05), whereas the total medication score of the placebo control group showed an insignificant decrease (P = 0.56). There were no systemic adverse reactions during the study.
CONCLUSIONS & CLINICAL RELEVANCE: Sublingual allergen-specific immunotherapy in elderly patients with a HDM allergy to D. pteronyssinus and D. farinae generated a significant clinical improvement in the active group compared with the placebo group, particularly during the heating season. This therapy was well tolerated.
Authors:
A Bozek; B Ignasiak; B Filipowska; J Jarzab
Related Documents :
12153335 - Spotlight on ziprasidone in schizophrenia and schizoaffective disorder.
7167045 - A cross-national study of drug treatment decisions in psychiatry.
2006695 - Relation of csf neurotensin concentrations to symptoms and drug response of psychotic p...
18423985 - Predicting response to atypical antipsychotics based on early response in the treatment...
18090035 - Effect of human placental extract on menopausal symptoms, fatigue, and risk factors for...
16205345 - A revised scoring system for preoperative evaluation of metastatic spine tumor prognosis.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology     Volume:  43     ISSN:  1365-2222     ISO Abbreviation:  Clin. Exp. Allergy     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-21     Completed Date:  2013-07-01     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  8906443     Medline TA:  Clin Exp Allergy     Country:  England    
Other Details:
Languages:  eng     Pagination:  242-8     Citation Subset:  IM    
Copyright Information:
© 2012 Blackwell Publishing Ltd.
Affiliation:
Clinical Department of Internal Disease, Dermatology and Allergology, Medical University School of Silesia, 41-800 Zabrze, Poland. andrzejbozek@o2.pl
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Sublingual
Aged
Animals
Antigens, Dermatophagoides / administration & dosage,  immunology*
Desensitization, Immunologic* / adverse effects
Female
Humans
Male
Middle Aged
Nasal Provocation Tests
Pyroglyphidae / immunology*
Rhinitis, Allergic, Perennial / diagnosis,  immunology*,  therapy*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antigens, Dermatophagoides
Comments/Corrections
Comment In:
Immunotherapy. 2013 Jul;5(7):699-702   [PMID:  23829621 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Specific patterns of allergic sensitization in early childhood and asthma & rhinitis risk.
Next Document:  Hypersensitivity reactions to the Sabin vaccine in children with cow's milk allergy.